Background: Pneumonia stands as a widely known contributor to hospitalization and mortality among adults in the United States. Meanwhile, disruptions in potassium homeostasis such as hyperkalemia may have an impact on in-patient mortality. This study seeks to examine the presence of hyperkalemia and its association with in-patient mortality among pneumonia patients.
Methods: Electronic medical records were used to perform a retrospective observational cohort study in Southwest Missouri patients admitted to the hospital with pneumonia and/or hyperkalemia. Patients were divided into three samples: patients with pneumonia and hyperkalemia (P1), pneumonia without hyperkalemia (P2), and hyperkalemia without pneumonia (P3). The goal was to determine and compare the in-patient mortality rates of these samples.
Results: Patients with both pneumonia and hyperkalemia (P1) demonstrated the highest mortality rate, ranging from 34.25% to 42.31%, significantly surpassing rates observed in patients with pneumonia without hyperkalemia (P2) or hyperkalemia without pneumonia (P3). Notably, patients with pneumonia without hyperkalemia (P2) exhibited a mortality rate comparable to patients with hyperkalemia without pneumonia (P3).
Conclusion: Our study revealed that patients admitted to the hospital with pneumonia and hyperkalemia had a statistically significant increase in mortality in comparison to patients with pneumonia or hyperkalemia independently. Recognizing this association may help identify prognosis and thus guide the management of patients admitted to the hospital with both hyperkalemia and pneumonia.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11888787 | PMC |
http://dx.doi.org/10.7759/cureus.78565 | DOI Listing |
Objective: Predicting the occurrence of hyperkalemia in patients undergoing co-trimoxazole treatment for Pneumocystis pneumonia is critical. However, other factors besides drug exposure affect serum potassium levels, and various interventions are often used to treat hyperkalemia in clinical practice. Therefore, we aimed to develop a Markov model to predict the risk of hyperkalemia under various intervention conditions.
View Article and Find Full Text PDFCureus
February 2025
Department of Primary Care, Kansas City University College of Osteopathic Medicine, Joplin, USA.
Background: Pneumonia stands as a widely known contributor to hospitalization and mortality among adults in the United States. Meanwhile, disruptions in potassium homeostasis such as hyperkalemia may have an impact on in-patient mortality. This study seeks to examine the presence of hyperkalemia and its association with in-patient mortality among pneumonia patients.
View Article and Find Full Text PDFCan J Infect Dis Med Microbiol
January 2025
, Department of Pharmacy Practice, School of Pharmacy, Lebanese American University, Chaghoury Building, 6 Floor, P.O. Box 36/ S 32, Byblos, Lebanon.
To evaluate the pharmacology, pharmacokinetics, pharmacodynamics, antimicrobial activity, efficacy, safety, and the regulatory status of sulbactam-durlobactam. Sulbactam-durlobactam is a recently approved antimicrobial combination of two -lactamase inhibitors for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) associated with -calcoaceticus complex (ABC) in patients 18 years and older. Sulbactam is a direct antibacterial activity with high susceptibility to species.
View Article and Find Full Text PDFJ Antimicrob Chemother
February 2025
Department of Pharmacy, The Ohio State University Wexner Medical Center, 410 W 10th Ave, Columbus, OH 43210, USA.
Objective: To compare the rate of clinical cure and adverse effects in patients receiving definitive treatment with trimethoprim-sulfamethoxazole versus minocycline monotherapy for Stenotrophomonas maltophilia pneumonia.
Methods: A single-centre, retrospective cohort study of patients with S. maltophilia pneumonia admitted 1 March 2018-30 September 2023 was conducted comparing treatment with trimethoprim-sulfamethoxazole versus minocycline monotherapy.
Front Endocrinol (Lausanne)
January 2025
Department of Nephrology, Affiliated Bao'an Hospital of Shenzhen, The Second School of Clinical Medicine, Southern Medical University, Shenzhen, China.
Objectives: The study will evaluate the effectiveness and safety of finerenone in patients diagnosed with diabetic kidney disease (DKD).
Methods: Various databases including PubMed, Sinomed, Web of Science, Embase, Clinical Trials, and Cochrane Library were systematically reviewed for pertinent studies published from the beginning to February 2024.This meta-analysis utilized RevMan 5.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!